By proceeding, you agree to our Terms of Use and Privacy Policy.
Kei Kishimoto Chief Scientific Officer at Selecta Biosciences
Talks About #medical
Preferred Locations #NorthAmerica
Welcome to the Optimizing AAV Safety Summit: Predict & Monitor AAV Safety Signals to De-Risk Genetic Therapy Development Hundreds of clinical trials using AAV are underway, with several hundred more in preclinical development.
The 6th Antigen-Specific Immune Tolerance Summit returns as the definitive industry-dedicated forum bringing you the latest discoveries, preclinical, translational, and early clinical developments on tolerogenic therapies.